Although the aberrant overexpression of COX-2, the BBS-like peptide, GRP, and GRPR has been documented for prostate cancers with NE features, particularly in the setting of recurrent disease [3,7,41], a mechanistic link between GRPR activation and COX-2 expression in prostate cancer cells has not been made. Here, GRP is linked to prostate cancer.